{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:41:50Z","timestamp":1780105310064,"version":"3.54.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.7759\/cureus.83244","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T11:22:42Z","timestamp":1746012162000},"source":"Crossref","is-referenced-by-count":1,"title":["Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review"],"prefix":"10.7759","author":[{"given":"Zach","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2020.1854194","article-title":"Ketamine for depression","volume":"33","author":"Jelen LA","year":"2021","unstructured":"Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021, 33:207-28. 10.1080\/09540261.2020.1854194","journal-title":"Int Rev Psychiatry"},{"key":"ref2","article-title":"A comprehensive review of the pathophysiology of depression","volume":"8","author":"Fouad MA","year":"2024","unstructured":"Fouad MA, Tadros MG, Michel HE. A comprehensive review of the pathophysiology of depression. Arch Pharm Sci Ain Shams Univ. 2024, 8:122-32.","journal-title":"Arch Pharm Sci Ain Shams Univ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab088","article-title":"Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT)","volume":"25","author":"Ekstrand J","year":"2022","unstructured":"Ekstrand J, Fattah C, Persson M, et al.. Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT). Int J Neuropsychopharmacol. 2022, 25:339-49. 10.1093\/ijnp\/pyab088","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109171","article-title":"Ketamine; history and role in anesthetic pharmacology","volume":"216","author":"Hirota K","year":"2022","unstructured":"Hirota K, Lambert DG. Ketamine; history and role in anesthetic pharmacology. Neuropharmacology. 2022, 216:109171. 10.1016\/j.neuropharm.2022.109171","journal-title":"Neuropharmacology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2023_447","article-title":"SSRIs in the treatment of depression: a pharmacological cul-de-sac?","volume":"66","author":"Cowen PJ","year":"2024","unstructured":"Cowen PJ. SSRIs in the treatment of depression: a pharmacological cul-de-sac?. Curr Top Behav Neurosci. 2024, 66:1-19. 10.1007\/7854_2023_447","journal-title":"Curr Top Behav Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: from monoamines to glutamate","volume":"23","author":"Hillhouse TM","year":"2015","unstructured":"Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015, 23:1-21. 10.1037\/a0038550","journal-title":"Exp Clin Psychopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa089","article-title":"Habenula connectivity and intravenous ketamine in treatment-resistant depression","volume":"24","author":"Rivas-Grajales AM","year":"2021","unstructured":"Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula connectivity and intravenous ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2021, 24:383-91. 10.1093\/ijnp\/pyaa089","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2018.12.002","article-title":"Lateral habenular burst firing as a target of the rapid antidepressant effects of ketamine","volume":"42","author":"Cui Y","year":"2019","unstructured":"Cui Y, Hu S, Hu H. Lateral habenular burst firing as a target of the rapid antidepressant effects of ketamine. Trends Neurosci. 2019, 42:179-91. 10.1016\/j.tins.2018.12.002","journal-title":"Trends Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, et al.. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023, 26:1032-41. 10.1038\/s41593-023-01316-5","journal-title":"Nat Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12169","article-title":"Equivalency of tricyclic antidepressants in open-label neuropathic pain study","volume":"129","author":"Liu WQ","year":"2014","unstructured":"Liu WQ, Kanungo A, Toth C. Equivalency of tricyclic antidepressants in open-label neuropathic pain study. Acta Neurol Scand. 2014, 129:132-41. 10.1111\/ane.12169","journal-title":"Acta Neurol Scand"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand A","year":"2023","unstructured":"Anand A, Mathew SJ, Sanacora G, et al.. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023, 388:2315-25. 10.1056\/NEJMoa2302399","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2058083","article-title":"BDNF blood levels after electroconvulsive therapy in patients with mood disorders: an updated systematic review and meta-analysis","volume":"24","author":"Pelosof R","year":"2023","unstructured":"Pelosof R, Santos LA, Farhat LC, Gattaz WF, Talib L, Brunoni AR. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: an updated systematic review and meta-analysis. World J Biol Psychiatry. 2023, 24:24-33. 10.1080\/15622975.2022.2058083","journal-title":"World J Biol Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120095","article-title":"Electroconvulsive therapy in treatment resistant depression","volume":"434","author":"Subramanian S","year":"2022","unstructured":"Subramanian S, Lopez R, Zorumski CF, Cristancho P. Electroconvulsive therapy in treatment resistant depression. J Neurol Sci. 2022, 434:120095. 10.1016\/j.jns.2021.120095","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4599","article-title":"Clinical outcomes of magnetic seizure therapy vs electroconvulsive therapy for major depressive episode: a randomized clinical trial","volume":"81","author":"Deng ZD","year":"2024","unstructured":"Deng ZD, Luber B, McClintock SM, Weiner RD, Husain MM, Lisanby SH. Clinical outcomes of magnetic seizure therapy vs electroconvulsive therapy for major depressive episode: a randomized clinical trial. JAMA Psychiatry. 2024, 81:240-9. 10.1001\/jamapsychiatry.2023.4599","journal-title":"JAMA Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305772120","article-title":"Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments","volume":"120","author":"Krystal JH","year":"2023","unstructured":"Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments. Proc Natl Acad Sci U S A. 2023, 120:e2305772120. 10.1073\/pnas.2305772120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike H","year":"2014","unstructured":"Koike H, Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 2014, 271:111-5. 10.1016\/j.bbr.2014.05.065","journal-title":"Behav Brain Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li N","year":"2010","unstructured":"Li N, Lee B, Liu RJ, et al.. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010, 329:959-64. 10.1126\/science.1190287","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.233","article-title":"The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN","volume":"41","author":"Fukumoto K","year":"2016","unstructured":"Fukumoto K, Iijima M, Chaki S. The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology. 2016, 41:1046-56. 10.1038\/npp.2015.233","journal-title":"Neuropsychopharmacology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx116","article-title":"Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine","volume":"21","author":"Fukumoto K","year":"2018","unstructured":"Fukumoto K, Iijima M, Funakoshi T, Chaki S. Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine. Int J Neuropsychopharmacol. 2018, 21:371-81. 10.1093\/ijnp\/pyx116","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08168-9","article-title":"Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects","volume":"10","author":"Hare BD","year":"2019","unstructured":"Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS. Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun. 2019, 10:223. 10.1038\/s41467-018-08168-9","journal-title":"Nat Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang K","year":"2019","unstructured":"Zhang K, Hashimoto K. Lack of opioid system in the antidepressant actions of ketamine. Biol Psychiatry. 2019, 85:e25-7. 10.1016\/j.biopsych.2018.11.006","journal-title":"Biol Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein ME","year":"2020","unstructured":"Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci U S A. 2020, 117:2656-62. 10.1073\/pnas.1916570117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2008.12.021","article-title":"Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass","volume":"23","author":"Hudetz JA","year":"2009","unstructured":"Hudetz JA, Patterson KM, Iqbal Z, et al.. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2009, 23:651-7. 10.1053\/j.jvca.2008.12.021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz EE","year":"2020","unstructured":"Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA, Park LT. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020, 263:568-75. 10.1016\/j.jad.2019.11.028","journal-title":"J Affect Disord"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.02.025","article-title":"Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions","volume":"236","author":"Riva-Posse P","year":"2018","unstructured":"Riva-Posse P, Reiff CM, Edwards JA, et al.. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord. 2018, 236:291-7. 10.1016\/j.jad.2018.02.025","journal-title":"J Affect Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000338098","article-title":"Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity","volume":"89","author":"Lai Y","year":"2012","unstructured":"Lai Y, Wu S, Ni L, et al.. Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity. Urol Int. 2012, 89:93-6. 10.1159\/000338098","journal-title":"Urol Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000002667","article-title":"Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder","volume":"130","author":"Sterpenich V","year":"2019","unstructured":"Sterpenich V, Vidal S, Hofmeister J, et al.. Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder. Anesthesiology. 2019, 130:923-35. 10.1097\/ALN.0000000000002667","journal-title":"Anesthesiology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly EJ","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, et al.. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019, 76:893-903. 10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough JW","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, et al.. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013, 74:250-6. 10.1016\/j.biopsych.2012.06.022","journal-title":"Biol Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh JB","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, et al.. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016, 173:816-26. 10.1176\/appi.ajp.2016.16010037","journal-title":"Am J Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0720-4","article-title":"Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis","volume":"26","author":"Kato M","year":"2021","unstructured":"Kato M, Hori H, Inoue T, et al.. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021, 26:118-33. 10.1038\/s41380-020-0720-4","journal-title":"Mol Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.0768","article-title":"Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy\/psychotherapy for treatment-resistant depression in the United States","volume":"75","author":"Ross EL","year":"2018","unstructured":"Ross EL, Zivin K, Maixner DF. Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy\/psychotherapy for treatment-resistant depression in the United States. JAMA Psychiatry. 2018, 75:713-22. 10.1001\/jamapsychiatry.2018.0768","journal-title":"JAMA Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.12.045","article-title":"Genetic evidence suggests a genetic association between major depressive disorder and reduced cortical gray matter volume: a Mendelian randomization study and mediation analysis","volume":"351","author":"Cai J","year":"2024","unstructured":"Cai J, Li Y, Liu X, et al.. Genetic evidence suggests a genetic association between major depressive disorder and reduced cortical gray matter volume: a Mendelian randomization study and mediation analysis. J Affect Disord. 2024, 351:738-45. 10.1016\/j.jad.2023.12.045","journal-title":"J Affect Disord"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.1.20","article-title":"Dissociating the clinical role and economic value of intranasal esketamine","volume":"26","author":"Dadiomov D","year":"2020","unstructured":"Dadiomov D. Dissociating the clinical role and economic value of intranasal esketamine. J Manag Care Spec Pharm. 2020, 26:20-2. 10.18553\/jmcp.2020.26.1.20","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/364263-neuropharmacology-of-ketamine-and-its-use-in-the-treatment-of-major-depressive-disorder-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T11:22:51Z","timestamp":1746012171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/364263-neuropharmacology-of-ketamine-and-its-use-in-the-treatment-of-major-depressive-disorder-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.83244","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}